Cell and Gene Logistics

  1. Deciding When Research Grade Raw Materials Are Sufficient 12/4/2025

    Qualifying raw materials is an investment, but mimicking the manufacturing process at small scales lowers the risk of throwing out material because it doesn't work at large ones, Lawrence Thompson said during this segment of Cell & Gene Live "Viability On The Line."

  2. Balancing Innovation With Manufacturability When GMP-Grade Is Unavailable 12/4/2025

    Some raw materials simply aren't available in GMP. Experts Yan Zhi and Lawrence Thompson describe risk assessment approaches that inform sourcing decisions in this segment from Cell & Gene Live "Viability On The Line." Some investigational therapies require many unique raw materials, and controlling them appropriately gets tricky. Complexities also vary by modality and batch size. Control strategies must be adaptable.

  3. Building Supply Chain Resilience When Dual-Sourcing Isn't An Option 12/4/2025

    Crafting a resilient supply chain, one where redundancy is out of the question, is easier said than done. Robust communication with suppliers helps ensure mutual understanding of needs. Preventing waste is a no-brainer but challenging to execute. Thoroughly characterizing critical quality attributes may offer some flexibility in choosing raw materials, in some cases, when they become scarce.

  4. Resilience By Design: Lessons From Real-World Disruption 12/2/2025

    Resilience is the bridge to patient access. Discover how to design your logistics with intentional flexibility to withstand real-world disruptions and protect product integrity under pressure.

  5. Why Supply Chain Integration Matters In Advanced Therapy Manufacturing 12/2/2025

    Fragmented supply chains increase risk and delay execution. Integration is key to establish a unified framework that enhances control, reduces administrative burden, and ensures program predictability.

  6. Why Shipping System Qualification Matters In Advanced Therapies 12/2/2025

    Ensuring the integrity of advanced therapies requires documented evidence of robust shipping processes. Qualification is essential for compliance and maintaining continuity across the supply chain.

  7. Built Or Bought? Why Biotechs Are Outsourcing Supply Chain Infrastructure 12/2/2025

    Scaling advanced therapies requires navigating extreme logistics and regulatory hurdles. Learn why moving to a flexible, outsourced model is essential for freeing capital and mitigating global risk.

  8. Formulation And Delivery Considerations For Cell And Gene Therapies 11/25/2025

    How can we ensure cell and gene therapies are truly transformative for patients? Success depends on the right combination of formulation, preparation, and delivery.

  9. Cell And Gene Therapy Commercialization Handbook 11/24/2025

    Bringing advanced therapeutics to market requires overcoming hurdles in regulation, logistics, and reimbursement. Learn how to coordinate supply chains and implement adaptive strategies for long-term commercial success.

  10. What You Should Expect From Your Cell Culture Media Supplier 11/14/2025

    Discover how a superior cell culture media supplier provides a VIP experience through seamless ordering, proactive demand planning, and customization to accelerate your project to market.